Dr Roger Thompson

All publications

Journal articles

• Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, Sidhu JK, Ascough S, Moore SC, Mohamed N , Nunag J et al (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25(4), 607-621.
• Varian F, Dick J, Battersby C, Roman S, Ablott J, Watson L, Binmahfooz S, Zafar H, Colgan G, Cannon J , Suntharalingam J et al (2024) Pulmonary hypertension: intensification and personalization of combination Rx (PHoenix): a phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies. Pulmonary Circulation, 14(1). View this article in WRRO
• Dwivedi K, Sharkey M, Delaney L, Alabed S, Rajaram S, Hill C, Johns C, Rothman A, Mamalakis M, Thompson AAR , Wild J et al (2024) Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT. Radiology, 310(2).
• Lord JM, Veenith T, Sullivan J, Sharma-Oates A, Richter AG, Greening NJ, McAuley HJC, Evans RA, Moss P, Moore SC , Turtle L et al (2024) Accelarated immune ageing is associated with COVID-19 disease severity. Immunity & Ageing, 21. View this article in WRRO
• Kiely DG, Hamilton N, Wood S, Durrington C, Exposto F, Muzwidzwa R, Raiteri L, Beaudet A, Muller A, Sauter R , Pillai N et al (2024) Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service. BMJ Open, 14(1). View this article in WRRO
• Taquet M, Skorniewska Z, Zetterberg H, Geddes JR, Mummery CJ, Chalmers JD, Ho L-P, Horsley A, Marks M, Poinasamy K , Raman B et al (2023) Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. Brain Communications, 6(1).
• Michael BD, Dunai C, Needham EJ, Tharmaratnam K, Williams R, Huang Y, Boardman SA, Clark JJ, Sharma P, Subramaniam K , Wood GK et al (2023) Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14(1), 8487.
• Brightling CE, Evans RA, Singapuri A, Smith N, Wain LV, Brightling CE, Evans RA, Wain LV, Chalmers JD, Harris VC , Ho LP et al (2023) Long COVID research: an update from the PHOSP-COVID Scientific Summit. The Lancet Respiratory Medicine, 11(11), e93-e94.
• Baillie JK, Lone NI, Jones S, Shaw A, Hairsine B, Kurasz C, Henson H, Armstrong L, Shenton L, Dobson H , Dell A et al (2023) Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. The Lancet Respiratory Medicine.
• Zheng B, Vivaldi G, Daines L, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M , Saunders RM et al (2023) Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls. The Lancet Regional Health - Europe, 100635-100635.
• Alkhanfar D, Dwivedi K, Alandejani F, Shahin Y, Alabed S, Johns C, Garg P, Thompson AAR, Rothman AMK, Hameed A , Charalampopoulos A et al (2023) Non-invasive detection of severe PH in lung disease using magnetic resonance imaging. Frontiers in Cardiovascular Medicine, 10.
• Jackson C, Stewart ID, Plekhanova T, Cunningham PS, Hazel AL, Al-Sheklly B, Aul R, Bolton CE, Chalder T, Chalmers JD , Chaudhuri N et al (2023) Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. The Lancet Respiratory Medicine.
• Saunders LC, Collier GJ, Chan H-F, Hughes PJC, Smith LJ, Watson J, Meiring J, Gabriel Z, Newman T, Plowright M , Wade P et al (2023) Longitudinal lung function assessment of patients hospitalised with COVID-19 using 1H and 129Xe lung MRI. Chest.
• McAuley HJC, Evans RA, Bolton CE, Brightling CE, Chalmers JD, Docherty AB, Elneima O, Greenhaff PL, Gupta A, Harris VC , Harrison EM et al (2023) Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. eClinicalMedicine, 57, 101896-101896.
• Astley JR, Biancardi AM, Hughes PJC, Marshall H, Collier GJ, Chan H, Saunders LC, Smith LJ, Brook ML, Thompson R , Rowland‐Jones S et al (2023) Implementable deep learning for multi-sequence proton MRI lung segmentation: a multi-center, multi-vendor, and multi-disease study. Journal of Magnetic Resonance Imaging.
• Bhagwani AR, Ali M, Piper B, Liu M, Hudson J, Kelly N, Bogamuwa S, Yang H, Londino JD, Bednash JS , Farkas D et al (2023) A p53-TLR3 axis ameliorates pulmonary hypertension by inducing BMPR2 via IRF3. iScience, 26(2).
• Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C , Moore SC et al (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine, 87.
• Stewart I, Jacob J, George PM, Molyneaux PL, Porter JC, Allen RJ, Aslani S, Baillie JK, Barratt SL, Beirne P , Bianchi SM et al (2022) Residual lung abnormalities following COVID-19 hospitalization: interim analysis of the UKILD post-COVID study. American Journal of Respiratory and Critical Care Medicine.
• Berendsen RR, Bärtsch P, Basnyat B, Berger MM, Hackett P, Luks AM, Richalet J-P, Zafren K, Kayser B, Anholm J , Auerbach PS et al (2022) Strengthening altitude knowledge: a delphi study to define minimum knowledge of altitude illness for laypersons traveling to high altitude. High Altitude Medicine and Biology.
• Sammut MA, Condliffe R, Elliot C, Hameed A, Lewis R, Kiely DG, Kyriacou A, Middleton JT, Raithatha A, Rothman A , Thompson AAR et al (2022) Atrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: comparison of rate versus rhythm control approaches. International Journal of Cardiology.
• Keir HR, Long MB, Abo-Leyah H, Giam YH, Vadiveloo T, Pembridge T, Hull RC, Delgado L, Band M, McLaren-Neil F , Adamson S et al (2022) Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. The Lancet Respiratory Medicine. View this article in WRRO
• Prapa M, Lago-Docampo M, Swietlik EM, Montani D, Eyries M, Humbert M, Welch CCL, Chung W, Berger RMF, Bogaard HJ , Danhaive O et al (2022) First genotype-phenotype study in TBX4 syndrome : gain-of-function mutations causative for lung disease. American Journal of Respiratory and Critical Care Medicine.
• The Lancet Digital Health (2022) Big data and long COVID. The Lancet Digital Health, 4(7), e477-e477.
• Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD , Gall H et al (2022) Phenotyping of idiopathic pulmonary arterial hypertension : a registry analysis. The Lancet Respiratory Medicine.
• Taylor S, Isobe S, Cao A, Contrepois K, Benayoun BA, Jiang L, Wang L, Melemenidis S, Ozen MO, Otsuki S , Shinohara T et al (2022) Endogenous retroviral elements generate pathologic neutrophils in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine.
• Grist JT, Collier GJ, Walters H, Kim M, Chen M, Abu Eid G, Laws A, Matthews V, Jacob K, Cross S , Eves A et al (2022) Lung abnormalities depicted with hyperpolarized Xenon MRI in patients with Long COVID. Radiology, 305(3).
• Goh ZM, Balasubramanian N, Alabed S, Dwivedi K, Shahin Y, Rothman AMK, Garg P, Lawrie A, Capener D, Thompson AAR , Alandejani F et al (2022) Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response.. Heart. View this article in WRRO
• Relph KA, Russell CD, Fairfield CJ, Turtle L, de Silva TI, Siggins MK, Drake TM, Thwaites RS, Abrams S, Moore SC , Hardwick HE et al (2022) Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission. Open Forum Infectious Diseases, 9(5).
• Evans RA, Leavy OC, Richardson M, Elneima O, McCauley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC , Houchen-Wolloff L et al (2022) Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. The Lancet Respiratory Medicine.
• Alkhanfar D, Shahin Y, Alandejani F, Dwivedi K, Alabed S, Johns C, Lawrie A, Thompson AAR, Rothman AMK, Tschirren J , Uthoff JM et al (2022) Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative CT. ERJ Open Research.
• Dowey R, Cole J, Roger Thompson AA, Hull RC, Huang C, Whatmore J, Iqbal A, Bradley KL, McKenzie J, Lawrie A , Condliffe AM et al (2022) Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin. ERJ Open Research, 8(2). View this article in WRRO
• Alandejani F, Hameed A, Tubman E, Alabed S, Shahin Y, Lewis RA, Dwivedi K, Mahmood A, Middleton J, Watson L , Alkhanfar D et al (2022) Imaging and risk stratification in pulmonary arterial hypertension : time to include right ventricular assessment. Frontiers in Cardiovascular Medicine, 9. View this article in WRRO
• Närhi F, Moonesinghe SR, Shenkin SD, Drake TM, Mulholland RH, Donegan C, Dunning J, Fairfield CJ, Girvan M, Hardwick HE , Ho A et al (2022) Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet Digital Health, 4(4), e220-e234.
• Turton HA, Pickworth J, Paterson GG, Lawrie A, Baillie JK & Thompson AAR (2022) Soluble P-selectin and von Willebrand factor rise in healthy volunteers following non-exertional ascent to high altitude. Frontiers in Physiology, 13. View this article in WRRO
• Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A , Nutalai R et al (2022) SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 185(3), 467-484.e15.
• Sullivan MK, Lees JS, Drake TM, Docherty AB, Oates G, Hardwick HE, Russell CD, Merson L, Dunning J, Nguyen-Van-Tam JS , Openshaw P et al (2022) Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study : a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), 271-284.
• Norris T, Razieh C, Zaccardi F, Yates T, Islam N, Gillies CL, Chudasama YV, Rowlands AV, Davies MJ, McCann GP , Banerjee A et al (2021) Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart.
• Kariotis S, Jammeh E, Swietlik EM, Pickworth JA, Rhodes CJ, Otero P, Wharton J, Iremonger J, Dunning MJ, Pandya D , Mascarenhas TS et al (2021) Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12. View this article in WRRO
• de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, Hsu NS, Shah D, Wellington D, Mentzer AJ, Angyal A , Brown R et al (2021) The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience, 24(11). View this article in WRRO
• Hurst EA, Mellanby RJ, Handel I, Griffith DM, Rossi AG, Walsh TS, Shankar-Hari M, Dunning J, Homer NZ, Denham SG , Devine K et al (2021) Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors : a cross-sectional study. BMJ Open, 11(10).
• Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC , Daines L et al (2021) Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.. The Lancet Respiratory Medicine.
• Abdukahil SA, Abe R, Abel L, Absil L, Acker A, Adachi S, Adam E, Adrião D, Ainscough K, Hssain AA , Tamlihat YA et al (2021) COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection, 49(5), 889-905.
• Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, Loney C, Herder V, Allan J, Jarmson I , Cameron-Ruiz N et al (2021) A prenylated dsRNA sensor protects against severe COVID-19. Science.
• Wild JM, Porter JC, Molyneaux PL, George PM, Stewart I, Allen RJ, Aul R, Baillie JK, Barratt SL, Beirne P , Bianchi SM et al (2021) Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respiratory Research, 8(1).
• Haque A, Kiely DG, Kovacs G, Thompson AAR & Condliffe R (2021) Pulmonary hypertension phenotypes in patients with systemic sclerosis. European Respiratory Review, 30(161), 210053-210053.
• Drake TM, Riad AM, Fairfield CJ, Egan C, Knight SR, Pius R, Hardwick HE, Norman L, Shaw CA, McLean KA , Thompson AAR et al (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. The Lancet, 398(10296), 223-237. View this article in WRRO
• Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, Pathak GA, Andrews SJ, Kanai M, Veerapen K , Fernandez-Cadenas I et al (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), 472-477. View this article in WRRO
• Errington N, Iremonger J, Pickworth JA, Kariotis S, Rhodes CJ, Rothman AMK, Condliffe R, Elliot CA, Kiely DG, Howard LS , Wharton J et al (2021) A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 69, 103444-103444.
• Leclerc QJ, Fuller NM, Keogh RH, Diaz-Ordaz K, Sekula R, Semple MG, Baillie JK, Semple MG, Openshaw PJM, Carson G , Alex B et al (2021) Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC Health Services Research, 21. View this article in WRRO
• Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, Sigfrid L, Harrison EM, Docherty AB, de Silva TI , Egan C et al (2021) Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study : a multicentre, prospective cohort study. The Lancet Microbe. View this article in WRRO
• The Lancet Rheumatology (2021) Going viral: misinformation in the time of COVID-19. The Lancet Rheumatology, 3(6), e393-e393.
• Docherty AB, Mulholland RH, Lone NI, Cheyne CP, De Angelis D, Diaz-Ordaz K, Donegan C, Drake TM, Dunning J, Funk S , García-Fiñana M et al (2021) Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. The Lancet Respiratory Medicine.
• Garg P, Lewis RA, Johns CS, Swift AJ, Capener D, Rajaram S, Thompson AAR, Condliffe R, Elliot CA, Charalampopoulos A , Hameed AG et al (2021) Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging.
• Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, Hardwick HE, Docherty AB, Thwaites RS, Openshaw PJM , Baillie JK et al (2021) Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. The Lancet Rheumatology. View this article in WRRO
• Bloom CI, Drake TM, Docherty AB, Lipworth BJ, Johnston SL, Nguyen-Van-Tam JS, Carson G, Dunning J, Harrison EM, Baillie JK , Semple MG et al (2021) Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 : a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. The Lancet Respiratory Medicine.
• Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, Abubakar I, Lipman M, Quartagno M, Pius R , Buchan I et al (2021) Development and validation of the ISARIC 4C deterioration model for adults hospitalised with COVID-19: a prospective cohort study. The Lancet Respiratory Medicine.
• Zawia A, Arnold ND, West L, Pickworth JA, Turton H, Iremonger J, Braithwaite AT, Cañedo J, Johnston SA, Thompson AAR , Miller G et al (2021) Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension.. Arteriosclerosis, thrombosis, and vascular biology, 41(1), 430-445. View this article in WRRO
• Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD , Furniss J et al (2020) Genetic mechanisms of critical illness in Covid-19. Nature.
• Sadiku P, Willson JA, Ryan EM, Sammut D, Coelho P, Watts ER, Grecian R, Young JM, Bewley M, Arienti S , Mirchandani AS et al (2020) Neutrophils fuel effective immune responses through gluconeogenesis and glycogenesis. Cell Metabolism. View this article in WRRO
• Goh ZM, Alabed S, Shahin Y, Rothman AMK, Garg P, Lawrie A, Capener D, Thompson AAR, Alandejani FAA, Johns CS , Lewis RA et al (2020) Right ventricular adaptation assessed using cardiac magnetic resonance predicts survival in pulmonary arterial hypertension. JACC: Cardiovascular Imaging.
• Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, Babu S, Barber CM, Barratt S, Bendstrup E , Bianchi S et al (2020) Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. American Journal of Respiratory and Critical Care Medicine, 202(12), 1656-1665. View this article in WRRO
• Lewis RA, Billings CG, Hurdman JA, Smith IA, Austin M, Armstrong IJ, Middleton J, Rothman AMK, Harrington J, Hamilton N , Hameed AG et al (2020) Maximal exercise testing using the incremental shuttle walking test can be used to risk stratify patients with pulmonary arterial hypertension. Annals of the American Thoracic Society.
• Bhagwani A, Thompson AAR & Farkas L (2020) When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension.. Frontiers in medicine, 7, 352. View this article in WRRO
• Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A, Church AC, Coghlan JG, Davies RJ, Dimopoulos K , Elliot C et al (2020) EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study. European Respiratory Journal. View this article in WRRO
• Lewis RA, Thompson AAR, Billings CG, Charalampopoulos A, Elliot CA, Hamilton N, Hill C, Hurdman J, Rajaram S, Sabroe I , Swift AJ et al (2020) Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension.. The European respiratory journal, 55(6). View this article in WRRO
• Rhodes CJ, Otero-Núñez P, Wharton J, Swietlik EM, Kariotis S, Harbaum L, Dunning MJ, Elinoff JM, Errington N, Thompson AAR , Iremonger J et al (2020) Whole Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 0(ja), 586-594. View this article in WRRO
• Turton HA, Thompson AAR & Farkas L (2020) RNA signaling in pulmonary arterial hypertension-a double-stranded sword. International Journal of Molecular Sciences, 21(9). View this article in WRRO
• Lewis RA, Billings CG, Bolger A, Bowater S, Charalampopoulos A, Clift P, Elliot CA, English K, Hamilton N, Hill C , Hurdman J et al (2020) Partial anomalous pulmonary venous drainage in patients presenting with suspected pulmonary hypertension: A series of 90 patients from the ASPIRE registry. Respirology. View this article in WRRO
• Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, Charalampopoulos A, Sabroe I, Thompson AAR, Billings CG , Hamilton N et al (2020) Identification of cardiac MRI thresholds for risk stratification in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 201(4), 458-468. View this article in WRRO
• Paterson GG, Young JM, Willson JA, Graham CJ, Dru RC, Lee EW, Torpey GS, Walmsley SR, Chan MV, Warner TD , Baillie JK et al (2020) Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and Haemostasis, 120(02), 253-261. View this article in WRRO
• Arnold ND, Pickworth JA, West LE, Dawson S, Carvalho JA, Casbolt H, Braithwaite AT, Iremonger J, Renshall L, Germaschewski V , McCourt M et al (2019) A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
• Rahman A, Henry KM, Herman KD, Thompson AA, Isles HM, Tulotta C, Sammut D, Rougeot JJ, Khoshaein N, Reese AE , Higgins K et al (2019) Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.. Elife, 8. View this article in WRRO
• Young JM, Williams DR & Thompson AAR (2019) Thin Air, Thick Vessels: Historical and Current Perspectives on Hypoxic Pulmonary Hypertension. Frontiers in Medicine, 6. View this article in WRRO
• Billings CG, Lewis R, Hurdman JA, Condliffe R, Elliot C, Thompson AAR, Smith IA, Austin M, Armstrong IJ, Hamilton N , Charalampopoulos A et al (2019) Express: The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.. Pulmonary Circulation. View this article in WRRO
• Farkas D, Thompson AAR, Bhagwani AR, Hultman S, Ji H, Kotha N, Farr G, Arnold ND, Braithwaite A, Casbolt H , Cole JE et al (2019) Toll-like receptor 3 is a therapeutic target for pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 199(2). View this article in WRRO
• Quadery SR, Swift AJ, Billings C, Thompson AAR, Elliot CA, Hurdman J, Charalampopoulos A, Sabroe I, Armstrong I, Hamilton N , Sephton P et al (2018) The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 52(3). View this article in WRRO
• Taylor S, Dirir O, Zamanian R, Rabinovitch M & Thompson AAR (2018) The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. Frontiers in Medicine, 5. View this article in WRRO
• Roach RC, Hackett PH, Oelz O, Bärtsch P, Luks AM, MacInnis MJ, Baillie JK, Achatz E, Albert E, Andrews JS , Anholm JD et al (2018) The 2018 Lake Louise Acute Mountain Sickness Score. High Altitude Medicine & Biology, 19(1), 4-6.
• Rocke A, Paterson G, Barber M, Jackson A, Main S, Stannett C, Schnopp M, Baillie J, Horne E, Moores C , Harrison P et al (2018) Thromboelastometry and Platelet Function during Acclimatization to High Altitude. Thrombosis and Haemostasis, 118(01), 063-071. View this article in WRRO
• Renshall L, Arnold N, West L, Braithwaite A, Pickworth J, Walker R, Alfaidi M, Chamberlain J, Casbolt H, Thompson AAR , Holt C et al (2018) Selective improvement of pulmonary arterial hypertension with a dual ET A /ET B receptors antagonist in the apolipoprotein E −/− model of PAH and atherosclerosis. Pulmonary Circulation, 8(1), 1-11. View this article in WRRO
• Feng S, Bowden N, Fragiadaki M, Souilhol C, Hsiao S, Mahmoud M, Allen S, Pirri D, Ayllon BT, Akhtar S , Thompson AAR et al (2017) Mechanical Activation of Hypoxia-Inducible Factor 1α Drives Endothelial Dysfunction at Atheroprone Sites.. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(11), 2087-2101. View this article in WRRO
• Sadiku P, Willson JA, Dickinson RS, Murphy F, Harris AJ, Lewis A, Sammut D, Mirchandani AS, Ryan E, Watts ER , Thompson AAR et al (2017) Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses.. Journal of Clinical Investigation, 127(9), 3407-3420. View this article in WRRO
• Thompson AAR, Dickinson RS, Murphy F, Thomson JP, Marriott HM, Tavares A, Willson J, Williams L, Lewis A, Mirchandani A , Coelho PDS et al (2017) Hypoxia determines survival outcomes of bacterial infection through HIF-1α-dependent reprogramming of leukocyte metabolism. Science Immunology, 2(8). View this article in WRRO
• Thompson AAR & Lawrie A (2017) Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends in Molecular Medicine, 23(1), 31-45. View this article in WRRO
• Lodge KM, Thompson AAR, Chilvers ER & Condliffe AM (2016) Hypoxic regulation of neutrophil function and consequences for Staphylococcus aureus infection. Microbes and Infection. View this article in WRRO
• Hickey PM, Thompson AA, Charalampopoulos A, Elliot CA, Hamilton N, Kiely DG, Lawrie A, Sabroe I & Condliffe R (2016) Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. European Respiratory Journal, 48(5), 1514-1514.
• Jones R, McDonald KE, Willson JA, Ghesquière B, Sammut D, Daniel E, Harris AJ, Lewis A, Thompson AAR, Dickinson RS , Plant T et al (2016) Mutations in succinate dehydrogenase B (SDHB) enhance neutrophil survival independent of HIF-1α expression. Blood, 127(21), 2641-2644. View this article in WRRO
• Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AAR, Wauters E, Walmsley S, Prenen H, Granot Z , Casazza A et al (2015) MET is required for the recruitment of anti-tumoural neutrophils. Nature, 522(7556), 349-353. View this article in WRRO
• Thompson AAR, Walmsley SR & Whyte MKB (2014) A local circadian clock calls time on lung inflammation. Nature Medicine, 20(8), 809-811.
• Hall DP, MacCormick IJC, Phythian-Adams AT, Rzechorzek NM, Hope-Jones D, Cosens S, Jackson S, Bates MGD, Collier DJ, Hume DA , Freeman T et al (2014) Network analysis reveals distinct clinical syndromes underlying acute mountain sickness.. PloS one, 9(1), e81229. View this article in WRRO
• Thompson AAR, Elks PM, Marriott HM, Eamsamarng S, Higgins KR, Lewis A, Williams L, Parmar S, Shaw G, McGrath EE , Formenti F et al (2014) Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish. Blood, 123(3), 366-376.
• Thompson AA, Binham J, Plant T, Whyte MK & Walmsley SR (2013) Hypoxia, the HIF pathway and neutrophilic inflammatory responses. Biological Chemistry, 394(4), 471-477.
• MacCormick IJC, Somner J, Morris DS, MacGillivray TJ, Bourne RRA, Huang SS, MacCormick A, Aspinall PA, Baillie JK, Thompson AAR & Dhillon B (2012) Retinal Vessel Tortuosity in Response to Hypobaric Hypoxia. HIGH ALTITUDE MEDICINE & BIOLOGY, 13(4), 263-268.
• Marriott HM, Daigneault M, Thompson AAR, Walmsley SR, Gill SK, Witcher DR, Wroblewski VJ, Hellewell PG, Whyte MKB & Dockrell DH (2012) A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia. Thorax, 67(11), 985-992. View this article in WRRO
• McGrath EE, Lawrie A, Marriott HM, Mercer P, Cross SS, Arnold N, Singleton V, Thompson AAR, Walmsley SR, Renshaw SA , Sabroe I et al (2012) Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. Thorax, 67(9), 796-803. View this article in WRRO
• Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I , Dockrell DH et al (2011) Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. Journal of Clinical Investigation, 121(3), 1053-1063. View this article in WRRO
• Walmsley SR, Chilvers ER, Thompson A, Vaughan K, Marriott H, Parker L, Shaw G, Parmar S, Schneider M, Sabroe I , Dockrell D et al (2011) Prolyl Hydroxylase Phd3 Is Essential For Hypoxic Regulation Of Neutrophilic Inflammation. C13. PATHOGENESIS OF ACUTE LUNG INJURY.
• Bates MGD, Thompson AAR, Baillie JK, Sutherland AI, Irving JB, Hirani N & Webb DJ (2011) Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial. High Altitude Medicine and Biology, 12(3), 207-214.
• McGovern NN, Cowburn AS, Porter L, Walmsley SR, Summers C, Thompson AAR, Anwar S, Willcocks LC, Whyte MKB, Condliffe AM & Chilvers ER (2011) Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophils. Journal of Immunology, 186(1), 453-463.
• Jackson SJ, Varley J, Sellers C, Josephs K, Codrington L, Duke G, Njelekela MA, Drummond G, Sutherland AI, Thompson AAR & Baillie JK (2010) Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro.. High Alt Med Biol, 11(3), 217-222.
• Thompson AAR, Raistrick CS, Pirzada OM & Anderson PB (2010) A complication of peroral bronchoscopy. EUR RESPIR J, 35(1), 221-222.
• Thompson AAR, Baillie JK, Bates MGD, Schnopp MF, Simpson A, Partridge RW, Drummond GB & Mason NP (2009) The citric acid cough threshold and the ventilatory response to carbon dioxide on ascent to high altitude.. Respir Med, 103(8), 1182-1188.
• Baillie JK, Thompson AAR, Irving JB, Bates MGD, Sutherland AI, Macnee W, Maxwell SRJ & Webb DJ (2009) Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial.. QJM, 102(5), 341-348.
• Toshner MR, Thompson AAR, Irving JB, Baillie JK, Morton JJ & Peacock AJ (2008) NT-proBNP Does Not Rise on Acute Ascent to High Altitude. HIGH ALT MED BIOL, 9(4), 307-310.
• Mytton OT, Simpson A, Thompson AAR, Oram RA, Darowski A, Yu LM, Collier DJ & Pollard AJ (2008) Manual Assessment of the Initial Fall in Blood Pressure After Orthostatic Challenge at High Altitude. WILD ENVIRON MED, 19(4), 225-232.
• Baillie JK, Bates MGD, Thompson AAR, Waring WS, Partridge RW, Schnopp MF, Simpson A, Gulliver-Sloan F, Maxwell SRJ & Webb DJ (2007) Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude.. Chest, 131(5), 1473-1478.
• Bates MGD, Thompson AAR & Baillie JK (2007) Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. CURR OPIN INVESTIG D, 8(3), 226-231.
• Dorward DA, Thompson AAR, Baillie JK, MacDougall M & Hirani N (2007) Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness.. Respir Med, 101(3), 587-594.
• Thompson AAR, McRoberts RJ, McKie S & Oglesby AJ (2006) Catastrophe for a campanologist.. Eur J Emerg Med, 13(3), 184-186.
• Thompson AAR, Baillie JK, Toshner M, Maxwell SRJ, Webb DJ & Irving JB (2006) Pericardial effusions in healthy lowlanders after acute ascent to high altitude. HEART, 92(4), 539-540.
• Smith EMD, Baillie JK, Thompson AAR, Irving JB, Porteous D & Webb DJ (2006) Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude. HIGH ALT MED BIOL, 7(3), 221-227.
• Alhathli E, Julian T, Girach ZUA, Thompson AAR, Rhodes C, Gräf S, Errington N, Wilkins MR, Lawrie A, Wang D & Cooper‐Knock J () Mendelian Randomization Study With Clinical Follow‐Up Links Metabolites to Risk and Severity of Pulmonary Arterial Hypertension. Journal of the American Heart Association.
• Gilmour A, Hughes C, Giam YH, Hull RC, Pembridge T, Abo-Leyah H, Thompson AR, Condliffe AM, Shoemark A, Chalmers JD & Long MB () A serum calprotectin lateral flow test as an inflammatory and prognostic marker in acute lung infection: a prospective observational study. ERJ Open Research, 00059-02024.
• Durrington C, Hurdman JA, Elliot CA, Maclean R, Van Veen J, Sacccullo G, De-Foneska D, Swift AJ, Rajaram S, Hill C , Thomas S et al () Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. European Respiratory Journal, 2300846-2300846.
• Gupta V, Kariotis S, Rajab MD, Errington N, Alhathli E, Jammeh E, Brook M, Meardon N, Collini P, Cole J , Wild JM et al () Unsupervised machine learning to investigate trajectory patterns of COVID-19 symptoms and physical activity measured via the MyHeart Counts App and smart devices. npj Digital Medicine, 6(1).
• Elneima O, McAuley HJC, Leavy OC, Chalmers JD, Horsley A, Ho L-P, Marks M, Poinasamy K, Raman B, Shikotra A , Singapuri A et al () Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study. International Journal of Epidemiology.
• Roper KJ, Thomas J, Albalawi W, Maddocks E, Dobson S, Alshehri A, Barone FG, Baltazar M, Semple MG, Ho A , Turtle L et al () Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera. Scientific Reports, 13(1).
• Alabed S, Garg P, Alandejani F, Dwivedi K, Maiter A, Karunasaagarar K, Rajaram S, Hill C, Thomas S, Gossling R , Sharkey M et al () Establishing minimally important differences for cardiac MRI endpoints in pulmonary arterial hypertension. European Respiratory Journal, 2202225-2202225.
• Wardle M, Nair A, Saunders S, Armstrong I, Charalampopoulos A, Elliot C, Hameed A, Hamilton N, Harrington J, Keen C , Lewis R et al () Elective lower limb orthopaedic arthroplasty surgery in patients with pulmonary hypertension. Pulmonary Circulation.
• Billings CG, Lewis R, Armstrong IJ, Hurdman JA, Smith IA, Austin M, Elliot CA, Charalampopoulos A, Sabroe I, Lawrie A , Thompson AAR et al () Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. Frontiers in Medicine, 5. View this article in WRRO
• Walmsley S, Harris A, Thompson AAR & Whyte MKB () HIF-mediated innate immune responses: cell signaling and therapeutic implications. Hypoxia, 47-47. View this article in WRRO
• Bauchmuller K, Condliffe R, Southern J, Billings C, Charalampopoulos A, Elliot CA, Hameed A, Kiely DG, Sabroe I, Thompson AAR , Raithatha A et al () Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. ERJ Open Research, 00046-2021.
• Thompson AAR, Wilkins MR, Wild JM, Kiely DG & Lawrie A () Editorial : pulmonary hypertension : mechanisms and management, history and future. Frontiers in Medicine, 7. View this article in WRRO

Conference proceedings papers

• Pearce LMD, Bakr A, Strickland S, Gustafsson L, Ng KL, Thomas S, Newman T, Plowright M, Watson J, Gabriel Z , Rodgers J et al (2023) S81 Assessment of endothelial function in Long-COVID and in patients with residual lung abnormalities after COVID-19. ‘Bad blood’ – Biomarkers and mechanisms in long COVID
• Ng KL, Saunders L, Collier G, Grist J, Strickland S, Gustafsson L, Smith L, Evans RI, Vuddamalay G, Walters H , Jones SA et al (2023) S20 Long-COVID: a multi-faceted syndrome explored in the EXPLAIN study (HypErpolarised xenon magnetic resonance PuLmonary ImAging In PatieNts with Long-COVID). ‘Shake it off’ – Recovery from COVID-19
• Saunders LC, Collier GJ, Smith LJ, Hughes PJC, Marshall H, Chan HF, Biancardi A, Grist J, Strickland S, Gustafsson L , Ho LP et al (2023) S19 Gas exchange imaging using dissolved-phase 129Xe MRI in post COVID cohorts. ‘Shake it off’ – Recovery from COVID-19
• Saunders L, Collier G, Chan H-F, Hughes P, Smith L, Marshall H, Brook M, Biancardi A, Rao M, Norquay G , Stewart N et al (2023) Impaired xenon gas transfer observed two years after COVID-19 hospitalisation in patients with signs of interstitial lung disease. Imaging
• Gilmour A, Hughes C, Long MB, Keir HR, Giam YH, Abo-Leyah H, Pembridge T, Delgado L, Hull RC, New BJ , Dowey R et al (2023) Evaluating the utility of a serum calprotectin lateral flow test in acute lung infection. Respiratory infections and bronchiectasis
• Collier G, Saunders L, Smith LJ, Ng K, Grist J, Swift AJ, Davies H, Horsley A, Thompson AAR, Fraser E , Gleeson F et al (2023) Age, sex and lung volume dependence of 129Xe MRI gas exchange metrics. Clinical respiratory physiology, exercise and functional imaging
• Battersby C, Condliffe R, Kiely DG, Elliot C, Middleton JT, Patel J, Neelam-Naganathan D, Lewis R, Binmahfooz S, Swift AJ , Hameed A et al (2023) 155 Effect of covid-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension. Heart Failure
• Middleton J, Elliot C, Pearson C, Battersby C, Roman S, Armstrong I, Condliffe R, Watson L, Rothman AMK, Neelam-Naganathan D , Kiely DG et al (2023) 137 Design and validation of a physiological risk score for pulmonary arterial hypertension (pah). Heart Failure
• Middleton J, Neelam-Naganathan D, Elliot C, Taylor J, Toshner M, Zafar H, Lewis R, Ashraf C, Binmahfooz S, Condliffe R , Durrington C et al (2023) 138 Physiological detection of clinical worsening and therapeutic response using implanted remote technologies in pah. Heart Failure
• Taylor J, Kiely DG, Hamilton N, Hurdman J, Dwivedi K, Pearson C, Charalampopoulos A, Zafar H, Reddy A, Lewis R , Patel J et al (2023) 153 Differences in physical activity, heart rate and heart variability during clinical worsening events in patients with pulmonary arterial hypertension (pah). Heart Failure
• Ashraf C, Taylor J, Roddis C, Toshner M, Middleton JT, Hurdman J, Thompson R, Kiely DG, Swift AJ, Charalampopoulos A , Roman S et al (2023) 154 Stability of daily physical activity as a remote measure of clinical risk in pulmonary arterial hypertension (pah). Heart Failure
• Varian F, Binmahfooz S, Condliffe R, Middleton JT, Rothman AMK, Patel J, Kiely DG, Hamilton N, Lewis R, Elliot C , Battersby C et al (2023) 158 Remote personalisation of pulmonary arterial hypertension therapy and application of a remote physiological risk score. Heart Failure
• Patel J, Kiely DG, Roddis C, Charalampopoulos A, Thompson R, Pearson C, Dick J, Binmahfooz S, Lewis R, Taylor J , Ashraf C et al (2023) 196 The relationship of physical activity, heart rate variability, and night heart rate to established measures of clinical risk in patients with pulmonary arterial hypertension (pah). Stable IHD/Prevention/Hypertension/Lipids
• Zafar H, Passman J, Sandy R, Wright C, Wright F, Evans H, Ebah L, Ilyas D, Hanumapura P, Sebastien S , Khalifa A et al (2023) BS74 Assessment of fluid status in porcine models of heart failure and pulmonary hypertension. Basic Science
• Lawrie A, Zawia A, West L, Arnold N, Pickworth J, Turton H, Thompson AAR & Francis SE (2023) Osteoprotegerin Has Distinct Roles in Pulmonary Vascular and Cardiac Remodelling in a Mouse Model of Pulmonary Arterial Hypertension. A14. THIS IS GETTING COMPLICATED: EPIGENETICS, -OMICS, AND CELL SIGNALING IN PULMONARY HYPERTENSION
• Schwiening M, Moore S, Nibhani R, Crosby A, Southwood M, Dunmore B, Turton H, Thompson R, Morrell NW, Marciniak SJ & Soon E (2023) Unpicking the Effects of General Control Non-depressible 2 (GCN2) Deficiency in Pulmonary Veno-Occlusive Disease. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
• Durrington C, Hurdman J, Armstrong I, Charalampopoulos A, Condliffe R, Elliot C, De-Fonseka D, Hameed AG, Hamilton N, Hill C , Maclean R et al (2023) Systematic Follow-up of Patients Following Acute Pulmonary Embolism Identifies High Incidence of Chronic Thromboembolic Pulmonary Hypertension: ASPIRE CTEPH. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
• Durrington C, Battersby C, Holt L, Fairman A, salisbury T, Turton H, Watson L, Hameed A, Charalampopoulos A, Elliot C , Rothman A et al (2023) Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH). B57. INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD
• Kim Y, Kim H, Liu Y, Klouda T, Schumacher V, Thompson R, Wu JC, Li JB, Raby BA & Yuan K (2023) ADAR1 Mediated RNA Editing Contributes to Vascular Remodeling in PAH. D18. MOLECULAR TRAFFIC HUBS IN PULMONARY VASCULAR DISEASE
• Keir HR, Long MB, Abo-Leyah H, Giam YH, Vadiveloo T, Pembridge T, Hull RC, Delgado L, Band M, Mclaren-Neil F , Adamson S et al (2022) Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized with COVID-19: a Multicentre Randomized Double-Blind Placebo Controlled Trial. 10.01 - Respiratory infections and bronchiectasis
• Haque A, Divwedi K, Lewis R, Charalampopoulos A, Elliot C, Hameed A, Hamilton N, Ramjug S, Rothman A, Swift A , Thompson R et al (2022) The effect of parenchymal lung disease on patient characteristics and outcome in SSc-PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
• Haque A, Charalampopoulos A, Dwivedi K, Elliot C, Hameed A, Hamilton N, Lewis R, Ramjug S, Rothman A, Thompson R , Swift A et al (2022) New diagnostic criteria and PVR thresholds in SSc-associated PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
• Alabed S, Dwivedi K, Durrington C, Alandejani F, Lewis R, Eelliot C, Charalampopoulos A, Thompson R, Hameed A, Rothman A , Armstrong I et al (2022) Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
• Veale N, Shuvo ER, Schwiening M, Soares F, Feng O, Abreu S, Thomas W, Thompson R, Samworth RJ, Morrell NW , Marciniak SJ et al (2022) P169 Non-generalisability of biomarkers for mortality in SARS-CoV-2. ‘Infinity War’ – Ongoing clinical challenges in COVID-19
• Battersby CP, Middleton JT, Zafar H, Binmahfooz SK, Patel J, Neelam-Naganathan D, Toshner M, Reddy A, Lewis R, Watson L , Swift A et al (2022) P81 Effect of COVID-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension. ‘Contagion’ – The impact of COVID-19
• Middleton JT, Binmafooz S, Zafar H, Patel J, Giri D, Battersby C, Toshner M, Reddy A, Lewis R, Durrington C , Swift A et al (2022) S92 Remote monitoring enabled evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
• Alabed S, Dwivedi K, Durrington C, Alandajani F, Condliffe R, Elliot C, Charalampopoulos A, Hameed A, Thompson R, Rothman A , Armstrong I et al (2022) P37 Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. ‘Mission (Im)possible I’ – Pulmonary vascular disease
• Patel J, Middleton J, Battersby C, Zafar H, Binmahfooz S, Neelam-Naganathan D, Toshner M, Reddy A, Lewis R, Watson L , Swift A et al (2022) S91 Remote monitored physical activity is related to established measures of clinical risk in patients with pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
• Goh ZM, Balasubramanian N, Alabed S, Dwivedi K, Shahin Y, Rothman AMK, Garg P, Lawrie A, Capener D, Thompson AAR , Alandejani F et al (2022) S90 Right ventricular remodelling assessed using cardiac magnetic resonance predicts survival and treatment response in pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
• Durrington C, Armstrong I, Charalampopoulos A, Condliffe R, Devey T, Elliot C, Hameed A, Hamilton N, Hill C, Hurdman J , Lewis RA et al (2022) S93 Systematic follow-up of patients following acute pulmonary embolism is associated with an increased incidence of chronic thromboembolic pulmonary hypertension and less severe disease. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
• Durrington C, Battersby C, Holt L, Fairman A, Salisbury T, Turton H, Watson L, Hameed AG, Charalampopoulos A, Elliot CA , Rothman AMK et al (2022) P38 Assessing the repeatability of NT-proBNP testing using laboratory and point of care testing in PAH (REPEAT-PAH). ‘Mission (Im)possible I’ – Pulmonary vascular disease
• Middleton JT, Binmahfooz S, Zafar H, Patel J, Giri D, Battersby C, Toshner M, Reddy A, Lewis R, Condliffe R , Elliot C et al (2022) Abstract 13553: Remote Monitoring of the Haemodynamic Response to Clinically Indicated Therapeutic Escalation and Clinical Worsening Events in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13553-a13553)
• Middleton JT, Binmahfooz S, Zafar H, Patel J, Naganathan DGN, Battersby C, Toshner M, Reddy A, Lewis R, Swift AJ , Condliffe R et al (2022) Abstract 13527: The Development of a Remote Pulmonary Arterial Hypertension Risk Score Utilising Remote Monitoring Technology to Monitor Parameters Associated With Mortality in Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13527-a13527)
• Kim H, Liu Y, Klouda T, Schumacher VA, Thompson AA, Wu JC, Li JB, Raby B & Yuan K (2022) Abstract 10848: Adar1 Mediated Rna Editing Contributes to Vascular Remodeling. Circulation, Vol. 146(Suppl_1) (pp a10848-a10848)
• Thompson AAR, Meiring JE, Holbourn A, Cole J, Hockridge J, Metherall P, Lawson RA, Rajaram S & Swift AJ (2022) Lung Subtraction Iodine Mapping in Breathless Patients After COVID-19. C30. LIFE AND LUNGS AFTER COVID: FUNCTIONAL RECOVERY AND OUTCOMES FOLLOWING SARS-CoV2 INFECTION (pp a3914-a3914)
• Long MB, Keir HR, Giam YH, Abo-Leyah H, Pembridge T, Delgado L, Hull R, Gilmour A, Hughes C, New BJM , Dowey R et al (2022) Transcriptomic Changes in Hospitalised COVID19 Patients Across 29 Days Provide Insight into the Systemic Immune Response and Disease Outcomes: Results from PREDICT-COVID19. D17. TOP KNOWLEDGE IN COVID (pp a5050-a5050)
• Keir HR, Long MB, Abo Leyah H, Giam YH, Vadiveloo T, Pembridge T, Hull R, Delgado L, Band M, McLaren-Neill F , Adamson S et al (2022) A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial. D17. TOP KNOWLEDGE IN COVID (pp a5055-a5055)
• Errington N, Kariotis S, Jammeh E, Fong Y-L, Lihan Z, Chen H, Jatkoe T, Bridges C, Vener T, Wharton J , Thompson R et al (2022) Unsupervised Clustering of PH Using Circulating miRNA - Towards Molecular Classification of PH?. B96. FISHERMAN'S WHARF: OMICS AND TRANSLATIONAL APPROACHES IN PULMONARY VASCULAR DISEASE (pp a3440-a3440)
• Kariotis S, Jammeh E, Swietlik EM, Rhodes CJ, Errington N, Thompson R, Wharton J, Coghlan G, Lordan J, Corris P , Howard LS et al (2022) Longitudinal Analysis of Three Major Risk-Associated Transcriptomic Subgroups Within the IPAH Classification. C55. NOB HILL: CELLULAR ORIGINS OF PULMONARY VASCULAR DISEASE (pp a4432-a4432)
• Condliffe R, Bauchmuller K, Southern J, Billings C, Charalampopoulos A, Elliot C, Hameed A, Kiely D, Sabroe I, Thompson R , Raithatha A et al (2021) Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. Pulmonary hypertension
• Sammut MA, Condliffe R, Hameed A, Rothman AM, Kyriacou A, Lewis RA, Durrington C, Elliot CA, Thompson AA, Sabroe I , Kiely DG et al (2021) Abstract 13581: Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. Circulation, Vol. 144(Suppl_1)
• Middleton J, Zafar H, Reddy A, Martin C, Thompson R, Swift A, Toshner M, Kiely DG & Rothman A (2021) 121 Effect of UK COVID-19 public health measures on activity and quality of life in patients with pulmonary arterial hypertension. Heart failure
• Maranthe N, Austin M, Billings C, Elliot C, Charalampopoulos A, Hameed A, Hamilton N, Kiely DG, Lewis R, Sabroe I , Smith I et al (2021) P140 Comparison of different measures of diffusion capacity in suspected systemic sclerosis associated pulmonary arterial hypertension. The nuts and bolts of ILD clinical management
• Sammut MA, Condliffe R, Hameed A, Rothman AM, Kyriacou A, Lewis RA, Durrington C, Elliot CA, Thompson AA, Sabroe I & Kiely DG (2021) Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. CIRCULATION, Vol. 144
• Middleton JT, Konganige S, Dahaghin P, Zafar H, Reddy A, Martin C, Thompson AAR, Swift AJ, Morris P, Condliffe R , Morrell NW et al (2020) Abstract 15636: Effect of COVID-19 Public Health Measures on Activity and Quality of Life in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 142(Suppl_3) View this article in WRRO
• Lewis RA, Kelly T, Drew E, Billings CG, Hurdman J, Smith I, Austin M, Armstrong IJ, Middleton J, Rothman AMK , Harrington J et al (2020) Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. Pulmonary hypertension
• Lewis RA, Thompson AAR, Billings CG, Charalampopoulos A, Elliot C, Hamilton N, Hill C, Hurdman J, Rajaram S, Sabroe I , Swift AJ et al (2020) Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Pulmonary hypertension
• Lewis R, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A, Church AC, Coghlan JG, Davies R, Dimopoulos K , Elliot C et al (2020) EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study. Pulmonary hypertension
• Lawrie A, Arnold ND, Pickworth JA, West LE, Papworth J, Germaschewski V, Thompson AAR & Francis SE (2020) The Anti-Osteoprotegerin (OPG) Antibody Ky3 Attenuates OPG-Fas Mediated Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Pro-Inflammatory Signalling In Vitro and In Vivo. A107. BYSTANDERS NO MORE: INFLAMMATION, IMMUNITY AND THROMBOSIS IN PULMONARY VASCULAR AND LUNG DISEASE
• Lewis R, Cogliano M, Johns CS, Billings CG, Hamilton N, Elliot CA, Charalampopoulos A, Sabroe I, Thompson R, Condliffe R , Wild JM et al (2019) Cardiac MRI: Identifying Thresholds to Predict Mortality in Pulmonary Arterial Hypertension. B27. HEARTBREAKER: HEART FAILURE AND PULMONARY HYPERTENSION
• Lewis R, Billings C, Hurdman J, Smith I, Austin M, Armstrong I, Swift A, Rothman A, Charalampopoulos A, Sabroe I , Elliot C et al (2019) The Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Hypertension as Per the European Respiratory/Cardiac Society Guidelines. A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH
• Bhagwani AR, Farkas D, Goncharova EA, Thompson AAR & Farkas L (2019) Homeostatic Role for the P53-Dependent Toll-Like Receptor 3 Expression in the Pulmonary Endothelium. A97. STATION TO STATION: UNRAVELING THE MOLECULAR PATHOGENESIS OF PAH
• Braithwaite AT, Pickworth JA, Arnold ND, West LE, Iremonger JE, Thompson AA, Marriott HM & Lawrie A (2018) T6 Vascular smooth muscle derived TRAIL underlies pulmonary vascular remodelling in sugen 5416/hypoxia mice. BTS/BALR/BLF Early Career Investigators awards symposium
• Billings C, Lewis R, Hurdman J, Armstrong I, Smith I, Austin M, Elliot C, Charalampopoulos A, Sabroe I, Lawrie A , Thompson R et al (2018) Incremental Shuttle Walk Test predicts survival in non-Group 1 Pulmonary Hypertension without a ceiling effect. Pulmonary hypertension
• Billings C, Lewis R, Armstrong I, Hurdman J, Smith I, Austin M, Elliot C, Charalampopoulos A, Sabroe I, Lawrie A , Thompson R et al (2018) Incremental shuttle walking test distance is reduced in patients with pulmonary hypertension in WHO Functional Class I. Pulmonary hypertension
• Braithwaite AT, Pickworth JA, Arnold ND, West LE, Iremonger JE, Thompson AA, Marriott HM & Lawrie A (2018) Vascular Smooth Muscle Derived TRAIL is Required for Development of Pulmonary Arterial Hypertension in Sugen 5416 / Hypoxia Mice. CIRCULATION, Vol. 138
• ten Klooster L, Theodorou C, Wilson V, Selby K, Newton R, Gandhi S, Bonnett T, Fletcher J, Armstrong I, Martin L , Hamilton N et al (2017) Managing pregnancy in pulmonary hypertension using a multi-professional approach: a 16-year experience in a specialist referral centre. Pulmonary Circulation and Pulmonary Vascular Disease
• Quadery SR, Swift AJ, Billings C, Thompson AAR, Elliot CA, Hurdman J, Garrod S, Charalampopolous A, Sabroe I, Armstrong I , Hamilton N et al (2017) P183 Impact of patient choice on survival in patients with chronic thromboembolic pulmonary hypertension offered pulmonary endarterectomy. Pulmonary vascular disease: monitoring and managing
• Dirir O, Lodge KM, Creaser-Myers A, Walker S, Kiely DG, Condliffe AM, Lawrie A & Thompson AAR (2017) S111 Altered neutrophil phenotypes in pulmonary arterial hypertension. Advances in understanding chronic thrombo-embolic disease and pulmonary hypertension
• Klooster LT, Wilson V, Selby K, Newton R, Gandhi S, Bonnet T, Fletcher J, Armstrong I, Martin L, Hamilton N , Mills G et al (2017) P180 Managing pregnancy in pulmonary hypertension using a multi-professional approach: a 16-year experience in a specialist referral centre. Pulmonary vascular disease: monitoring and managing
• Dickinson RS, Thompson AAR, Thomson JP, Murphy F, Marriott HM, Tavares A, Willson J, Williams L, Lewis A, Forbes S , Stimson RH et al (2016) S104 Hypoxia preconditions the innate immune response to acute bacterial pulmonary infections. Thorax, Vol. 71(Suppl 3) (pp A61.2-A62)
• Thompson AAR, Arnold ND, Braithwaite AT, Casbolt HL, Iremonger J, Pickworth JA, Monaco C, Cole JE, Sabroe I & Lawrie A (2016) S87 Deficiency of toll-like receptor 3 (TLR3) exacerbates pulmonary hypertension in mice. Thorax, Vol. 71(Suppl 3) (pp A50.1-A50)
• Quadery SR, Condliffe RA, Billings C, Thompson R, Elliot CA, Charalampopolous A, Hurdman J, Hamilton N, Armstrong I, Sephton P , Sabroe I et al (2016) P28 Chronic thromboembolic pulmonary hypertension: long term outcomes in surgical and non-surgical patients. Thorax, Vol. 71(Suppl 3) (pp A98.1-A98)
• Thompson AAR, Arnold ND, Braithwaite AT, Casbolt HL, Pickworth JA, Cole JE, Monaco C, Kiely D, Sabroe I & Lawrie A (2016) Deficiency Of Toll-Like Receptor 3 (tlr3) Exacerbates Pulmonary Hypertension In Mice. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 193
• Sammut D, Lewis A, Budd R, Dickinson R, McDonald K, Harris AJ, Dockrell DH, Whyte MKB, Walmsley SR, Thompson A & Singh D (2015) Increased Reactive Oxygen Species Generation In Quiescent And Activated Peripheral Blood Neutrophils In Chronic Obstructive Pulmonary Disease. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 191
• Thompson AAR, Marriott HM, Williams L, Shaw G, Hameed A, Parmar S, Preston JA, Simon MC, Johnson RS, Foster SJ , Dockrell DH et al (2013) HYPOXIA INDUCES HYPOTHERMIA AND SICKNESS BEHAVIOUR IN MICE FOLLOWING SUBCUTANEOUS INJECTION OF LIVE STAPHYLOCOCCUS AUREUS. THORAX, Vol. 68 (pp A140-A140)
• Walmsley SR, Thompson AAR, Marriott H, Williams L, Lewis A, Sabroe I, Dockrell D, Taylor CT, Chilvers E, Pugh C , Ratcliffe P et al (2013) Differential Regulation Of Neutrophil (pmn) Survival By The Prolyl Hydroxylase Enzymes Phd2 And Phd3. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 187
• Thompson AAR, Elks PM, Marriott HM, Higgins KR, Parmar S, Shaw G, Eamsamarng S, McGrath EE, Formenti F, Van Eeden FJ , Kinnula VL et al (2012) HYPOXIA-INDUCIBLE FACTOR 2 alpha REGULATES NEUTROPHILIC INFLAMMATION IN HUMANS, MICE AND ZEBRAFISH. THORAX, Vol. 67 (pp A1-A1)
• Parmar S, Thompson AAR, Higgins KR, Sabroe I, Parker LC, Lawrie A, Arnold J, Walker S, Elliot CA, Condliffe R , Kiely DG et al (2012) Elucidating The Mechanism By Which Monocytes Can Inhibit Hypoxic PA-SMC Proliferation. D33. ASTHMA PATHOGENESIS
• Thompson AAR, Elks PM, Marriott HM, Higgins KR, Shaw G, Parmar S, Formenti F, Van Eden FJ, Pugh CW, Sabroe I , Dockrell DH et al (2012) HIF-2± Regulates Neutrophilic Inflammation In Humans, Mice And Zebrafish. C31. REGULATION OF LUNG INFLAMMATION
• Toshner M, Baillie JK, Suntharalingam J, Morton JJ, Thompson AAR & Peacock AJ (2007) The natriuretic response on acute ascent to high altitude. THORAX, Vol. 62 (pp A84-A84)
• Thompson AAR, Schnopp MF, Barber MT, Horn EH & Moores C (2006) High altitude exposure causes a reduction in PFA-100 (TM) closure time in humans: evidence of platelet activation or a result of increased haematocrit?. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 133 (pp 49-50)

Preprints

• Openshaw P, Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, Sidhu J, Ascough S, Moore S , Mohamed N et al (2023) Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease after COVID-19 hospitalisation, Research Square Platform LLC.
• Leavy OC, Russell RJ, Harrison EM, Lone NI, Kerr S, Docherty AB, Sheikh A, Richardson M, Elneima O, Greening NJ , Harris VC et al (2023) One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study, Cold Spring Harbor Laboratory.
• Varian F, Dick J, Battersby C, Roman S, Ablott J, Watson L, Binmahfooz S, Zafar H, Colgan G, Cannon J , Suntharalingam J et al (2023) Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHoenix): A phase IV randomised trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies, Cold Spring Harbor Laboratory.
• Alhathli E, Julian TH, Abideen Girach ZU, THOMPSON AAR, Rhodes CJ, Errington N, Wilkins MR, Lawrie A, Wang D, Cooper-Knock J & Gräf S (2023) A Mendelian randomization study with clinical follow-up links metabolites to risk and severity of pulmonary arterial hypertension, Cold Spring Harbor Laboratory.
• Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, Sidhu JK, Ascough S, Moore SC, Mohamed N , Nunag J et al (2023) Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease, Cold Spring Harbor Laboratory.
• Elneima O, McAuley HJC, Leavy OC, Chalmers JD, Horsley A, Ho L-P, Marks M, Poinasamy K, Raman B, Shikotra A , Singapuri A et al (2023) Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID), Cold Spring Harbor Laboratory.
• Middleton JT, Binmahfooz S, Zafar H, Patel J, Ashraf C, Taylor J, Neelam-Naganathan D, Battersby C, Pearson C, Roddis C , Roman S et al (2023) Remote evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension, Cold Spring Harbor Laboratory.
• Jackson C, Stewart I, Plekhanova T, Cunningham P, Hazel AL, Al-Sheklly B, Aul R, Bolton CE, Chalder T, Chalmers JD , Chaudhuri N et al (2022) The effects of sleep disturbance on dyspnoea and impaired lung function following COVID-19 hospitalisation: a prospective multi-centre cohort study, Cold Spring Harbor Laboratory.
• Shuvo MER, Schwiening M, Soares F, Feng O, Abreu S, Veale N, Thomas W, Thompson AAR, Samworth RJ, Morrell NW , Marciniak SJ et al (2022) Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analyses series, Cold Spring Harbor Laboratory.
• Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C , Moore SC et al (2022) Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination, Cold Spring Harbor Laboratory.
• Dowey R, Cole J, Thompson AAR, Huang C, Whatmore J, Iqbal A, Bradley KL, McKenzie J, Hull RC, Lawrie A , Condliffe AM et al (2021) Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the PKC inhibitor ruboxistaurin, medRxiv.
• Taylor S, Contrepois K, Benayoun BA, Jiang L, Isobe S, Wang L, Melemenidis S, Ozen MO, Otsuki S, Shinohara T , Sweatt AJ et al (2021) Endogenous Retroviral Elements Generate Pathologic Neutrophils and Elastase Rich Exosomes in Pulmonary Arterial Hypertension, bioRxiv.
• Stewart I, Jacob J, George PM, Molyneaux PL, Porter JC, Allen RJ, Baillie JK, Barratt SL, Beirne P, Bianchi SM , Blaikley JF et al () Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study, Cold Spring Harbor Laboratory.
• Prapa M, Lago-Docampo M, Swietlik EM, Montani D, Eyries M, Humbert M, Welch CCL, Chung WK, Berger RMF, Bogaard HJ , Danhaive O et al () First genotype-phenotype study in TBX4 syndrome: gain-of-function mutations causative for lung disease, Cold Spring Harbor Laboratory.
• Grist JT, Collier GJ, Walters H, Chen M, Eid GA, Laws A, Matthews V, Jacob K, Cross S, Eves A , Durant M et al () The Investigation of Pulmonary Abnormalities using Hyperpolarised Xenon Magnetic Resonance Imaging in Patients with Long-COVID, Cold Spring Harbor Laboratory.
• Saunders LC, Collier GJ, Chan H-F, Hughes PJC, Smith LJ, Watson J, Meiring J, Gabriel Z, Newman T, Plowright M , Eaden JA et al () Longitudinal lung function assessment of patients hospitalised with COVID-19 using ¹H and ¹²⁹Xe lung MRI, Cold Spring Harbor Laboratory.